Trastuzumab/chemotherapy combinations in metastatic breast cancer.
about
Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in JordanAnalysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study.FOXO1A is a target for HER2-overexpressing breast tumors.Mitogen-activated protein kinase activation in UV-induced signal transduction.Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance.Antibody-based enrichment of peptides on magnetic beads for mass-spectrometry-based quantification of serum biomarkersSafety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK.Sensitization of chemotherapy by anti-HER.NF-kappa B activation in human breast cancer specimens and its role in cell proliferation and apoptosis.Breast metastasis of salivary duct carcinoma in a patient: a case report.Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy.Monoclonal antibody mechanisms of action in cancer.Nuclear factor-kappaB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo.Salivary duct carcinoma: what is already known, and can we improve survival?The use of nanoparticulates to treat breast cancer.Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial.Disposition of paclitaxel (Taxol) and its metabolites in patients with advanced breast cancer (ABC) when combined with trastuzumab (Hercpetin).Clinicopathological Behavior and Treatment-related Outcome of Rare Salivary Duct Carcinoma: The Shaukat Khanum Memorial Cancer Hospital Experience
P2860
Q24813346-65690CF6-BEB9-4925-B3FA-D1293D34F740Q33236634-545D52D5-E831-43FB-BE0A-97F5B03D65E0Q33959090-D8477FA6-1FB8-44CF-8A35-F4618107B253Q35055502-199AF220-FDF4-471D-BB60-C9038CA18FECQ35624814-CEB4C70F-8418-4BA8-B0E4-C3A94697F230Q35751680-49EF199B-BAA4-4E8C-87DC-ECB8C8919EC1Q35863158-B7D5A01E-F017-4F4F-85D8-DFD54B3EE562Q35954213-D608C489-7E4C-4DAE-939F-680BDDCBE5F7Q35971557-7EDE1A47-2353-4C55-8831-7BC8FF6A5BB8Q36493317-08327761-FC81-44CB-9540-2B07B8DC3634Q36604000-AF7A6C40-8FE6-4E1A-9137-785D02A87023Q36847649-5FF56513-C15D-4BAA-85AC-42861CB630FDQ36961106-F1E4D984-F052-4B7C-8F6C-65DFA7B6F132Q37164261-2DB6A189-054D-417E-9373-31E4DE4DED7BQ38001863-BDD575B2-EF27-4306-BBF7-9FEEE55DC392Q45066468-8A9199D7-DD96-4FC4-8208-5AFAE3574684Q46679425-09C094F0-AB44-4183-984E-8D4CD5B3AD89Q46775542-A859FF02-059D-4975-9E43-007A0817825CQ57824048-364BB6F8-A188-47DA-82E2-E46E3B14AE19
P2860
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
@ast
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
@en
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
@nl
type
label
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
@ast
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
@en
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
@nl
prefLabel
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
@ast
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
@en
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
@nl
P356
P1433
P1476
Trastuzumab/chemotherapy combinations in metastatic breast cancer.
@en
P2093
Eric P Winer
Jennifer A Ligibel
P356
10.1053/SONC.2002.34054
P433
3 Suppl 11
P577
2002-06-01T00:00:00Z